Cargando…

NSCLC molecular testing in Central and Eastern European countries

BACKGROUND: The introduction of targeted treatments for subsets of non-small cell lung cancer (NSCLC) has highlighted the importance of accurate molecular diagnosis to determine if an actionable genetic alteration is present. Few data are available for Central and Eastern Europe (CEE) on mutation ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ryska, Ales, Berzinec, Peter, Brcic, Luka, Cufer, Tanja, Dziadziuszko, Rafal, Gottfried, Maya, Kovalszky, Ilona, Olszewski, Włodzimierz, Oz, Buge, Plank, Lukas, Timar, Jozsef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845184/ https://www.ncbi.nlm.nih.gov/pubmed/29523116 http://dx.doi.org/10.1186/s12885-018-4023-4

Ejemplares similares

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
por: Skrzypski, Marcin, et al.
Publicado: (2017)

New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown Primary
por: Krawczyk, Paweł, et al.
Publicado: (2022)

Testing for ROS1 in non-small cell lung cancer: a review with recommendations
por: Bubendorf, Lukas, et al.
Publicado: (2016)

Perspectives for Cancer Care and Research in Central and Eastern Europe
por: Zielinski, Christoph C., et al.
Publicado: (2023)

KIT Mutation Incidence and Pattern of Melanoma in Central Europe
por: Doma, V., et al.
Publicado: (2019)

Oral treatment with etoposide in small cell lung cancer – dilemmas and solutions
por: Rezonja, Renata, et al.
Publicado: (2013)

Comparison of Different ROS1 Immunohistochemistry Clones and Consistency with Fluorescence In Situ Hybridization Results in Non-Small Cell Lung Carcinoma
por: Dülger, Onur, et al.
Publicado: (2023)

Access to Novel Drugs for Non‐Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis
por: Cufer, Tanja, et al.
Publicado: (2019)

Editorial: Liquid biopsy—A great hope or just hype?
por: Ryška, Aleš
Publicado: (2023)

Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
por: Šutić, Maja, et al.
Publicado: (2021)

PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung
por: Janzic, Urska, et al.
Publicado: (2017)

Spinal Cord Glioneuronal Tumor with Rosetted Neuropil-Like Islands in Pediatric Age Group
por: Comunoglu, Nil, et al.
Publicado: (2014)

Concordance of PD-L1 expression and CD8(+) TIL intensity between NSCLC and synchronous brain metastases
por: Batur, Sebnem, et al.
Publicado: (2020)

Cancer epidemiology in Central and South Eastern European countries
por: Vrdoljak, Eduard, et al.
Publicado: (2011)

Biology of Metastasis With Focus on Proteases
por: Cufer, Tanja
Publicado: (2005)

Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management
por: Penault-Llorca, Frédérique, et al.
Publicado: (2022)

Heparin and Liver Heparan Sulfate Can Rescue Hepatoma Cells from Topotecan Action
por: Dudás, József, et al.
Publicado: (2014)

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients
por: Kukec, Renata Rezonja, et al.
Publicado: (2015)

Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment
por: Penault-Llorca, Frédérique, et al.
Publicado: (2022)

The Applicability of Haarlem Integrated Diagnostic System in Diffuse Glial Tumors and Molecular Methods Affecting Prognosis
por: Kaya Terzi, Neslihan, et al.
Publicado: (2019)

The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas
por: Kaya Terzi, Neslihan, et al.
Publicado: (2022)

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis
por: Lohinai, Zoltan, et al.
Publicado: (2017)

ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023
por: Cufer, Tanja, et al.
Publicado: (2023)

Inhibitory Effect of (2R)-1-(1-Benzofuran-2-yl)-N-propylpentan-2-amine on Lung Adenocarcinoma
por: Mervai, Zsolt, et al.
Publicado: (2019)

Radiotherapy in thoracic malignancies: the preface
por: Jassem, Jacek, et al.
Publicado: (2021)

Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer
por: Pelicon, Veronika, et al.
Publicado: (2023)

Tumor-produced, active Interleukin-1 β regulates gene expression in carcinoma-associated fibroblasts
por: Dudás, József, et al.
Publicado: (2011)

Clinical significance of histologic subtyping of malignant pleural mesothelioma
por: Brcic, Luka, et al.
Publicado: (2020)

Outsourcing predictive biomarker testing in non-small cell carcinoma: a personal view of pathologists
por: Brcic, Luka, et al.
Publicado: (2020)

Diagnosis and Molecular Profiles of Large Cell Neuroendocrine Carcinoma With Potential Targets for Therapy
por: Popper, Helmut, et al.
Publicado: (2021)

A rare pediatric tumor: thymic carcinoma mimicking acute rheumatoid fever
por: Erguven, Muferet, et al.
Publicado: (2014)

Programmed Death-Ligand-1 Expression in Non-Small Cell Lung Cancer and Prognosis
por: Şahin, Songül, et al.
Publicado: (2019)

Prädiktive Immunzytochemie beim nicht-kleinzelligen Lungenkarzinom
por: Brcic, Luka, et al.
Publicado: (2022)

Microsatellite instability in metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus: a retrospective study
por: Markoš, Pave, et al.
Publicado: (2018)

Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?
por: Jiraskova, Lucie, et al.
Publicado: (2019)

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
por: Drilon, Alexander, et al.
Publicado: (2022)

Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy
por: Omersa, Daniel, et al.
Publicado: (2016)

Proteoglycans/Glycosaminoglycans: From Basic Research to Clinical Practice
por: Tzanakakis, George, et al.
Publicado: (2014)

Diethylnitrosamine induces lung adenocarcinoma in FVB/N mouse
por: Mervai, Zsolt, et al.
Publicado: (2018)

Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents
por: Wrona, Anna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fp7udpk98ghnn98t5naggflif1